Canopy Growth CGC Stock Builds Turnaround Momentum After FY2026 Reset

Canopy Growth Corporation stocks have been trading up by 8.04 percent amid optimism over expanded cannabis legalization prospects.

Spot the Next Big Runner

Click Here for a Millionaire's POV on Trading CGC

SUBSCRIBE FOR ALERTS

JOIN 50,000+ ACTIVE TRADERS

Key Takeaways

FY2026 results show CGC’s core cannabis business back to top-line growth, driven by double‑digit gains in Canadian adult-use, medical, and international cannabis revenue.
The MTL Cannabis acquisition makes Canopy Growth the largest medical cannabis provider in Canada by revenue and helps flip the balance sheet to a $131.3M net cash position.
Management sharply cut free cash outflow and adjusted EBITDA losses, while still facing compressed gross margins, weaker Storz & Bickel performance, and sizable net losses.
Q4 EPS improved to -C$0.40 from -C$1.27 year over year, with revenue rising to C$84.7M as CGC framed FY2026 as a full reset around cost discipline and structure.
Brand momentum continues as Claybourne Frosted Flyers wins “Best Infused Pre-Roll” and expands nationwide with new multi-pack formats aimed at summer demand and convenience.

Live Update At 14:02:40 EDT: On Thursday, July 02, 2026 Canopy Growth Corporation stock [NASDAQ: CGC] is trending up by 8.04%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

CGC is trying to turn a broken story into a rebuilding story. The latest quarter shows revenue at about C$84.7M, up from C$78M a year earlier, and full-year FY2026 results confirm that core cannabis sales are growing again. That matters. For a stock stuck around the $1.00 area, any sign of sustainable growth is fuel for trading momentum.

On the chart, CGC has been bouncing in a tight band between roughly $0.92 and $1.06 over the last couple of weeks. Friday’s move from a $0.9581 open to a $1.025 close shows buyers willing to step in on dips, but not yet strong enough to push a clean breakout. Intraday, the 5‑minute candles cluster around $1.01–$1.03, showing heavy consolidation — a classic “coiled spring” setup many short-term traders watch.

More Breaking News

Fundamentally, CGC still loses money. Margins are deeply negative, with EBIT margin near -84% and profit margins heavily in the red. But the balance sheet is less dangerous than it used to be: total debt to equity sits near 0.33, and liquidity ratios are solid. For active traders, that combination — ugly earnings, improving trends, and a sub‑$2 price — often means volatility and opportunity, not comfort.

Why Traders Are Watching CGC Right Now

Canopy Growth is back on radar screens because the FY2026 numbers finally show top-line traction instead of just more bleeding. CGC posted 20% growth in Canadian adult-use, 18% in Canadian medical, and, in Q4, 27% Canada medical plus 68% international cannabis growth. Those are real acceleration figures, not rounding errors. For momentum traders, strong percentage gains off a low base often precede bigger sentiment shifts.

The MTL Cannabis acquisition is another key driver. CGC now claims the largest medical cannabis position in Canada by revenue, which gives it scale in a higher-margin, stickier channel. Just as important, the company shifted from net debt to about $131.3M in net cash through recapitalization. That balance-sheet flip removes a big overhang and gives CGC more breathing room to execute the turnaround without constant dilution fears dominating every bounce.

Still, this is far from a clean story. CGC’s reported gross margins compressed, Storz & Bickel revenues and margins went backwards, and net losses remain heavy. Q4 EPS at -C$0.40 is a huge improvement from -C$1.27, but it is still deep in the red. Management is guiding to positive adjusted EBITDA in FY2027, leaning on cost cuts, cultivation efficiencies, and MTL integration. Traders will treat that as a potential catalyst, not a done deal.

On the brand side, the Claybourne Frosted Flyers win at the 2026 Grow Up Awards and the expansion of those infused pre-roll multi-packs across Canada show that CGC is not just cutting costs; it is still playing offense in product innovation. Awards and new SKUs do not fix the balance sheet, but they help explain why adult-use sales are growing and why CGC can still capture consumer attention in a crowded market.

Conclusion

For active traders, CGC sits in that classic turnaround sweet spot: price near $1, real fundamental progress, but plenty of risk left on the table. Revenue is growing again, free cash burn is shrinking, and the balance sheet has swung to net cash. At the same time, margins are ugly, returns on capital are deeply negative, and the company relies on a FY2027 adjusted EBITDA target that still has to be earned quarter by quarter.

The recent price action reflects that tug of war. CGC keeps chopping between roughly $0.95 and $1.05, with tight intraday ranges around $1.01–$1.03. That tells experienced traders to be patient: wait for a clear break with volume, not a random one‑cent pop. If the market starts to truly believe in CGC’s 2027 profitability path, this kind of low‑priced name can re-rate fast. If execution stumbles, the same leverage works in reverse. As Tim Bohen, lead trainer with StocksToTrade says, “Success in trading is more about cutting losses quickly than finding winners.” That mindset matters with a name like CGC, where risk can shift quickly if the turnaround thesis cracks.

For now, CGC is a teaching chart for anyone studying turnarounds. You get improving EPS, a big strategic acquisition in MTL Cannabis, brand wins like Frosted Flyers, and still-brutal income-statement math all in one ticker. As Tim Sykes likes to say, “The market rewards preparation, not predictions.” Traders digging into CGC’s numbers, charts, and news flow are building that preparation — not hunting for a sure thing, but for a well-understood trade.

This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.

Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.

Check out our quick startup guide for new traders!

Ready to build your watchlists? Check out these curated lists:

Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.

Start Your Trial Now!